Fig. 4

Cell marker expression (% of cells) by flow cytometry of control and cells treated with doxorubicin (DOXO, 10 µg/mL); amniotic membrane stem cells (AMCs); and DOXO + AMC. a Progesterone receptor (PR), b Estrogen receptor (ER), (c) VEGF, (d) PCNA-3, (e) IL-10, (f) TGF-β1. Data are averaged (n ≥ 04 ± SEM) of expression. (%). Comparisions against control were performed with one-way analysis of variance (ANOVA) as a Bonferroni post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001